Free Trial
NASDAQ:CBUS

Cibus 5/9/2024 Earnings Report

Cibus logo
$1.59 +0.01 (+0.63%)
Closing price 04:00 PM Eastern
Extended Trading
$1.60 +0.01 (+0.94%)
As of 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cibus EPS Results

Actual EPS
-$1.12
Consensus EPS
-$1.01
Beat/Miss
Missed by -$0.11
One Year Ago EPS
-$5.45

Cibus Revenue Results

Actual Revenue
$0.55 million
Expected Revenue
$0.40 million
Beat/Miss
Beat by +$150.00 thousand
YoY Revenue Growth
N/A

Cibus Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cibus' next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules.

Conference Call Resources

Cibus Earnings Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Cibus Slides on Alliance with John Innes Centre
See More Cibus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cibus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cibus and other key companies, straight to your email.

About Cibus

Cibus (NASDAQ:CBUS) is a plant biotechnology company that specializes in developing novel crop traits through precision gene editing. Using its proprietary Rapid Trait Development System (RTDS), the company targets improvements in yield, stress tolerance and quality without introducing foreign DNA, enabling what it terms “non-transgenic” enhancements. Cibus’s platform supports accelerated discovery and development of traits that address key challenges in modern agriculture, including climate resilience, herbicide tolerance and nutritional performance.

Founded in 1999 and headquartered in San Diego, California, Cibus has built a track record of innovation in the agricultural biotechnology sector. The company pursued its initial public listing in 2017, providing capital to expand its R&D operations and forge collaborations with leading seed and crop protection firms. Over more than two decades, Cibus has scaled its research capabilities, adding laboratory, greenhouse and field-testing facilities to advance a growing pipeline of gene-edited trait candidates.

Cibus focuses on major row and specialty crops such as canola, potato, tomato and rice, working closely with seed companies and farmers to integrate its traits into commercial varieties. The company offers trait development services, licensing arrangements and co-development partnerships, leveraging its RTDS expertise to tailor solutions for diverse agronomic needs. Cibus has also engaged in strategic collaborations to explore applications of its technology in new crop genomes and trait classes.

Serving markets in North America, Europe and select emerging regions, Cibus collaborates with regional breeding programs and distribution partners to accelerate market adoption. The company is led by President and Chief Executive Officer Rob Rasmus, whose management team brings deep experience in plant biotechnology, seed industry operations and agricultural innovation. Under this leadership, Cibus continues to advance its mission of delivering sustainable, science-driven crop improvements for global agriculture.

View Cibus Profile

More Earnings Resources from MarketBeat